Tag: Trikafta

All

Most Children with CF Achieve Normal Lung Function with Triple Combination Therapy, Study Finds

An observational one-year study found the therapy significantly reduced lung disease severity and prevented disease progression in children aged 6 to 11 with cystic fibrosis.

Health Canada OKs Trikafta for Younger Children With Cystic Fibrosis
FDA Approves Trikafta For Pediatric Cystic Fibrosis
Study Uses Smartphone to Track Cystic Fibrosis
Trikafta triple-combo Therapy Safe for Cystic Fibrosis Patients Ages 6-11
Top 10 Medical Innovations for 2021 Include Trikafta, Bubble CPAP
How Has COVID-19 Affected Therapy Adherence in Cystic Fibrosis Patients?
Survey: Cystic Fibrosis Patients Receiving CFTR Modulators Had More Positive Health Outlooks

All

Trikafta Approved by FDA for Cystic Fibrosis

Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the CFTR gene, which is estimated to represent 90% of the cystic fibrosis population.

Vertex Reports Very Positive Ph1/Ph2 Data on Triple Therapies for CF

Tag: Trikafta

All

Most Children with CF Achieve Normal Lung Function with Triple Combination Therapy, Study Finds

Health Canada OKs Trikafta for Younger Children With Cystic Fibrosis

FDA Approves Trikafta For Pediatric Cystic Fibrosis

Study Uses Smartphone to Track Cystic Fibrosis

Trikafta triple-combo Therapy Safe for Cystic Fibrosis Patients Ages 6-11

Top 10 Medical Innovations for 2021 Include Trikafta, Bubble CPAP

How Has COVID-19 Affected Therapy Adherence in Cystic Fibrosis Patients?

Survey: Cystic Fibrosis Patients Receiving CFTR Modulators Had More Positive Health Outlooks

All

Trikafta Approved by FDA for Cystic Fibrosis

Vertex Reports Very Positive Ph1/Ph2 Data on Triple Therapies for CF

All

Sorry, No Posts Found

Sorry, No Posts Found

Respiratory Therapy

Our Parent Company

Key Resources

Helpful Links